Reason for request

Extension of indication

-


Clinical Benefit

Substantial

Substantial


Clinical Added Value

no clinical added value

MENVEO does not provide any improvement in actual benefit (IAB V, non-existent) in the prevention of invasive meningococcal infections caused by serogroups A, C, W135, Y in children from 2 to 10 years of age.